


2004 FEB 11 AM 9:58



IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF OHIO
EASTERN DIVISION

UNITED STATES OF AMERICA,)
)
)
 Plaintiff,)
)
)
 v.)
)
)
 JACK EDWIN SLINGLUFF, D.O.,)
)
)
 Defendant.)
)

~~INFORMATION~~
4:04 CR 074

CR. NO. _____
Title 21, Section 331
United States Code

JUDGE NUGENT


COUNT 1

The United States Attorney charges:

On or about May 21, 2001, in the Northern District of Ohio, Eastern Division, JACK EDWIN SLINGLUFF, D.O., did cause the introduction or delivery for introduction into interstate commerce of a new drug that was neither approved pursuant to Title 21, Section 355(b) or (j), Section 505 of the Federal Food, Drug, and Cosmetic Act, nor exempt from approval pursuant to Section 355(i), to wit: JACK EDWIN SLINGLUFF, D.O., caused thirty (30) vials of the unapproved new drug Amigdalina B-17 (AKA Laetrile) to be shipped from West Palm Beach, Florida, to Salem,



Ohio; in violation of Title 21, Sections 331(d), 355(a) and
333(a)(1), United States Code.




GREGORY A. WHITE
UNITED STATES ATTORNEY

I hereby certify that this instrument is a true and
correct copy of the original on file in my office.

Attest: Geri M. Smith, Clerk

U.S. District Court

Northern District of Ohio

By: 
Deputy Clerk